National clinical practice guidelines for allergen immunotherapy: An international assessment applying AGREE-II.

BACKGROUND: Since 1988, numerous allergen immunotherapy guidelines (AIT-GLs) have been developed by national and international organizations to guide physicians in AIT. Even so, AIT is still severely underused. OBJECTIVE: To evaluate AIT-GLs with AGREE-II, developed in 2010 by McMaster University methodologists to comprehensively evaluate GL quality. METHODS: Allergist, from different continents, knowledgeable in AIT and AGREE-II trained were selected into the project team. The project received methodologists' guidance. AIT-GLs in any language were sought from 1980 to 2016; AIT-GLs were AGREE II-evaluated by at least 2 team members, independently; discrepancies were resolved in a second round, by team discussion or methodologists' consulting. RESULTS: We found 31 AIT-GLs (15 post-2010), ranging from local consensus reports to international position papers (EAACI, AAAAI-ACAAI, WAO). Pre-2010 GLs scored 1.6-4.6 (23%-67%) and post-2010 GLs scored 2.1-6 (30%-86%), on a 7-point Likert scale. The highest scores went to: German-Austrian-Swiss (6.0), Mexican (5.1), and the AAAAI/ACAAI AIT-GL (4.7). These were also the only 3 GLs that received "yes" of both evaluators to the item: "I would recommend this GL for use." The domains of "Stakeholder involvement" and "Rigor of Development" only scored 3/7, and "Applicability" scored the lowest. Strikingly, newer GLs only scored clearly better in "Editorial independence" and "Global evaluation." CONCLUSIONS: In AIT-GLs, there is still a lot of room for improvement, especially in domains crucial for the dissemination. For some GLs, the "Scientific rigor" domain flawed. When resources are limited, transculturizing a high-quality GL might be preferable over developing a GL from zero. Our study and AGREE-II could help to select the best candidate. CLINICAL IMPLICATIONS: We here evaluate allergen immunotherapy guideline (AIT-GL) quality. Only high-quality AIT-GLs should be consulted for AIT management decisions. In low-resource settings, transculturization of these is preferred over developing low-quality guidelines.

Recommendations for the prevention and diagnosis of asthma in children: Evidence from international guidelines adapted for Mexico.

BACKGROUND: With the availability of high-quality asthma guidelines worldwide, one possible approach of developing a valid guideline, without re-working the evidence, already analysed by major guidelines, is the ADAPTE approach, as was used for the development of National Guidelines on asthma. METHODS: The guidelines development group (GDG) covered a broad range of experts from medical specialities, primary care physicians and methodologists. The core group of the GDG searched the literature for asthma guidelines 2005 onward, and analysed the 11 best guidelines with AGREE-II to select three mother guidelines. Key clinical questions were formulated covering each step of the asthma management. RESULTS: The selected mother guidelines are British Thoracic Society (BTS), GINA and GEMA 2015. Responses to the questions were formulated according to the evidence in the mother guidelines. Recommendations or suggestions were made for asthma treatment in Mexico by the core group, and adjusted during several rounds of a Delphi process, taking into account: 1. Evidence; 2. Safety; 3. Cost; 4. Patient preference - all these set against the background of the local reality. Here the detailed analysis of the evidence present in BTS/GINA/GEMA sections on prevention and diagnosis in paediatric asthma are presented for three age-groups: children with asthma ≤5 years, 6-11 years and ≥12 years. CONCLUSIONS: For the prevention and diagnosis sections, applying the AGREE-II method is useful to develop a scientifically-sustained document, adjusted to the local reality per country, as is the Mexican Guideline on Asthma.

Treacher-Collins syndrome and co-existing dermatomyositis.

BACKGROUND: Treacher-Collins syndrome, an autosomal dominantly inherited malformation of structures derived from the first and second branchial arch, has an incidence of 1:10,000 newborns. The prevalence of dermatomyositis at less than 24 years of age has been estimated at 1 per 100,000. The occurrence of both Treacher-Collins syndrome and dermatomyositis combined in the same patient should occur once in every 1,000,000,000 subjects. METHODS: We report a patient with Treacher-Collins syndrome who developed dermatomyositis at the age of 5 years. RESULTS: No other patient with both Treacher-Collins syndrome and an autoimmune disease has been reported. The thymus originates from the third branchial pouch and is unaffected by the syndrome. In Treacher-Collins syndrome the affected gene has been mapped to the fifth chromosome, while dermatomyositis is related to HLA B8 and DR3, coded on the sixth chromosome. No immunologic alteration has been described in patients with Treacher-Collins syndrome. CONCLUSION: This is the first report of a patient with Treacher-Collins syndrome and dermatomyositis. There is no genetic or physiopathologic explanation for the concurrence of both conditions.

Mecanismos inmunológicos de la inmunoterapia específica y controversias sobre su uso / Immunological mechanism of specific immunotherapy and controversy about its utilization

Recientemente han aparecido varios reportes contradictorios acerca del uso de la inmunoterapia específica para el tratamiento de las enfermedades alérgicas. Algunos estudios ponen en duda su eficacia y sus mecanismos de acción. En esta revisión se exponen los datos más recientes que se encuentran en la literatura acerca de los mecanismos inmunológicos que sustentan el buen manejo de la inmunoterapia y los estudios clínicos que encuentran buenos resultados clínicos con su uso. Finalmente exponemos algunos puntos interesantes que surgieron recientemente en esta controversia sobre el uso de inmunoterapia específica en asma y los comentarios que han aparecido en la literatura mundial

Survival up to 5 and 10 years of mexican pediatric patients with systemic lupus erythematosus. Overhaul of 23 years experience.

A retrospective overhaul of all the patients with Systemic Lupus Erythematosus, deceased or followed-up for at least 5 years within the Immunology Service of the Instituto Nacional de Pediatría (Mexico), since 1970 up to december 1993. The objective was to determine overlife of mexican childs attended in a govermental institution and secondary to get information about demographic characteristics, time from inicial manifestations to diagnosis, treatment received, frequent complications, most important sequelas, and deed causes. 65 clinical records were reviewed, 86.2% females and 13.8% males, ages from 2 to 18 years old; 20 months was the average from start of illnes to definitive diagnosis. Most patient's initial treatment was prednisone and cyclophosphamide, being modified according to response evaluated by clinical al laboratory follow-up. Fifty one patients (78.5%) survived, 60% from 5 to 10 years, and 40% more than 10 years. Fourteen patients died (21.5%). Most frequent complications were local and systemic infections, hemorragic cystitis and steroidal diabetes. Principal dead cause was sepsis. Mortality en Systemic Lupus Erythematosus patients continues being high. Many factors contribute for delay diagnosis, in its way responsable for poorer pronostic. As a pediatric hospital, follow-up is end at adulthood, what makes long term follow-up limited.